Niche diagnostics Target Wave 80’s focus on next-generation molecular diagnostics for hepatitis and HIV/AIDS to propose pilot programs with hospital labs and reference centers seeking high-clinical-value tests and streamlined workflows.

One test model Leverage their one patient-one test usage model to position bundled consumables and platform-agnostic cartridges, offering cost-per-test clarity that appeals to labs aiming to reduce wasted reagents and improve throughput.

Strategic partnerships Explore co-development and licensing opportunities with academic centers and Fraunhofer-led institutions to accelerate commercialization, provide technical validation, and expand platform compatibility for diverse diagnostic settings.

Early-stage validation Propose grant-funded or milestone-based pilots to demonstrate LMP-based TB sample prep and cartridge integration, emphasizing faster deployment in disposable closed systems to attract early adopters seeking safer, contained workflows.

Emerging market fit Position to adjacent high-value markets and platforms within the molecular diagnostics space by highlighting compatibility with EOSCAPE lineage and other platforms to widen potential lab footprints and enterprise adoption.